股本结构
单位：万股
| 公告日期 | 2025-11-18 | 2025-08-14 | 2025-03-13 | 2025-01-31 | 2025-01-28 | 2025-01-07 |
|---|---|---|---|---|---|---|
| 证券总股本 | 834.02 | 631.66 | 631.66 | 626.66 | 226.92 | 701.31 |
| 普通股本 | 41701.08 | 31582.86 | 31582.86 | 31332.86 | 11346.06 | 7013.06 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-04 | 2025-06-30 | 2025-03-11 | 2025-01-31 | 2025-01-27 | 2024-12-27 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：50
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-18 | 41701.08 | 未披露 | 定期报告 | 2025-11-04 |
| 2025-08-14 | 31582.86 | 未披露 | 定期报告 | 2025-06-30 |
| 2025-03-13 | 31582.86 | 未披露 | 定期报告 | 2025-03-11 |
| 2025-01-31 | 31332.86 | 未披露 |
更多>>
Securities offered 199,868,050 ordinary shares by the company
|
2025-01-31 |
| 2025-01-28 | 11346.06 | 未披露 | 定期报告 | 2025-01-27 |
| 2025-01-07 | 7013.06 | 未披露 | 定期报告 | 2024-12-27 |
| 2024-11-18 | 5866.06 | 未披露 | 定期报告 | 2024-11-11 |
| 2024-11-18 | 5742.06 | 未披露 | 定期报告 | 2024-09-30 |
| 2024-08-20 | 5576.05 | 未披露 | 定期报告 | 2024-06-30 |
| 2024-04-25 | 5411.05 | 未披露 | 定期报告 | 2024-04-15 |
| 2024-03-26 | 5215.05 | 未披露 | 定期报告 | 2024-03-15 |
| 2024-02-05 | 4811.55 | 未披露 |
更多>>
Common stock offered 757,5000 shares by the company
|
2024-02-05 |
| 2024-01-30 | 4054.05 | 未披露 | 定期报告 | 2024-01-29 |
| 2024-01-12 | 3790.70 | 未披露 | 定期报告 | 2024-01-11 |
| 2023-12-21 | 3789.78 | 未披露 | 定期报告 | 2023-12-21 |
| 2023-11-17 | 2791.93 | 未披露 | 定期报告 | 2023-11-01 |
| 2023-12-21 | 2781.41 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-08-11 | 2765.16 | 未披露 | 定期报告 | 2023-07-18 |
| 2023-08-17 | 2764.03 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-04-28 | 2643.80 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-04-28 | 2413.94 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of shares for cash
Transaction costs
|
2022-12-31 |
| 2022-09-23 | 2397.79 | 未披露 | 定期报告 | 2022-09-23 |
| 2022-07-07 | 2383.37 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of shares for cash
Transaction costs paid in shares
|
2022-06-30 |
| 2022-06-21 | 2381.64 | 未披露 | 定期报告 | 2022-06-09 |
| 2022-05-20 | 2325.79 | 未披露 | 定期报告 | 2022-05-15 |
| 2022-03-31 | 2320.38 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of shares for cash
|
2021-12-31 |
| 2021-11-09 | 2314.15 | 未披露 |
更多>>
1.ADSs offered 3,428,571 ADSs.
2.Unless otherwise indicated, the number of ordinary shares to be outstanding after the offering is based on 19,198,668 ordinary shares, DKK 1 nominal value per share, each outstanding as of September 30, 2021.
3.Evaxion Biotech A/S announced today the closing of its follow-on public offering of 3,942,856 American Depositary Shares ("ADSs"), at a public offering price of $7.00 per ADS, which includes the exercise in full of the underwriters’ option to purchase 514,285 additional ADSs, with each such ADS representing one ordinary share, DKK 1 nominal value per share, of Evaxion (the "Ordinary Shares"). The gross proceeds to the Company from the offering were approximately $27.6 million before deducting underwriting fees, commissions and other offering expenses. The Company’s ADSs are listed on the Nasdaq Capital Market in the United States and the ADSs trade under the symbol "EVAX". All ADSs were offered by the Company.
|
2021-11-09 |
| 2021-02-05 | 1919.87 | 未披露 |
更多>>
1.ADSs offered by the company 3,000,000 ADSs
2.The number of ordinary shares to be outstanding after the offering is based on 16,198,668 ordinary shares, DKK 1 nominal value per share, each outstanding as of January 4, 2021, after giving effect to the issuance and sale of 269,136 of ordinary shares on October 15, 2020, the 2-for-1 split of ordinary shares on January 4, 2021, and the 17-for-1 bonus shares issuance on January 4, 2021
|
2021-02-05 |
Securities offered 199,868,050 ordinary shares by the company
Common stock offered 757,5000 shares by the company
From December 31, 2021 to December 31, 2022
Issuance of shares for cash
Transaction costs
From March 31, 2022 to June 30, 2022
Issuance of shares for cash
Transaction costs paid in shares
From December 31, 2020 to December 31, 2021
Issuance of shares for cash
1.ADSs offered 3,428,571 ADSs.
2.Unless otherwise indicated, the number of ordinary shares to be outstanding after the offering is based on 19,198,668 ordinary shares, DKK 1 nominal value per share, each outstanding as of September 30, 2021.
3.Evaxion Biotech A/S announced today the closing of its follow-on public offering of 3,942,856 American Depositary Shares ("ADSs"), at a public offering price of $7.00 per ADS, which includes the exercise in full of the underwriters’ option to purchase 514,285 additional ADSs, with each such ADS representing one ordinary share, DKK 1 nominal value per share, of Evaxion (the "Ordinary Shares"). The gross proceeds to the Company from the offering were approximately $27.6 million before deducting underwriting fees, commissions and other offering expenses. The Company’s ADSs are listed on the Nasdaq Capital Market in the United States and the ADSs trade under the symbol "EVAX". All ADSs were offered by the Company.
1.ADSs offered by the company 3,000,000 ADSs
2.The number of ordinary shares to be outstanding after the offering is based on 16,198,668 ordinary shares, DKK 1 nominal value per share, each outstanding as of January 4, 2021, after giving effect to the issuance and sale of 269,136 of ordinary shares on October 15, 2020, the 2-for-1 split of ordinary shares on January 4, 2021, and the 17-for-1 bonus shares issuance on January 4, 2021